Immunome Inc (NASDAQ: IMNM) on Tuesday, plunged -4.10% from the previous trading day, before settling in for the closing price of $12.20. Within the past 52 weeks, IMNM’s price has moved between $6.13 and $30.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 33.43%. With a float of $48.99 million, this company’s outstanding shares have now reached $59.97 million.
The extent of productivity of a business whose workforce counts for 55 workers is very important to gauge.
Immunome Inc (IMNM) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Immunome Inc is 18.31%, while institutional ownership is 60.08%. The most recent insider transaction that took place on May 21 ’24, was worth 281,548. In this transaction President and CEO of this company bought 20,434 shares at a rate of $13.78, taking the stock ownership to the 419,636 shares. Before that another transaction happened on May 21 ’24, when Company’s Director bought 2,000 for $13.57, making the entire transaction worth $27,140. This insider now owns 9,615 shares in total.
Immunome Inc (IMNM) Performance Highlights and Predictions
As on 3/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.35 earnings per share (EPS) for the period falling under the consensus outlook (set at 0.58) by -0.93. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.43% per share during the next fiscal year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Immunome Inc (IMNM) is currently performing well based on its current performance indicators. A quick ratio of 10.18 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.54, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -2.48 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
The latest stats from [Immunome Inc, IMNM] show that its last 5-days average volume of 2.43 million was superior to 0.86 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 33.82%. Additionally, its Average True Range was 0.90.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 3.17%, which indicates a significant decrease from 11.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.83% in the past 14 days, which was lower than the 70.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.28, while its 200-day Moving Average is $14.26. Now, the first resistance to watch is $12.11. This is followed by the second major resistance level at $12.53. The third major resistance level sits at $12.83. If the price goes on to break the first support level at $11.39, it is likely to go to the next support level at $11.09. Assuming the price breaks the second support level, the third support level stands at $10.67.
Immunome Inc (NASDAQ: IMNM) Key Stats
Market capitalization of the company is 701.65 million based on 59,969K outstanding shares. Right now, sales total 14,020 K and income totals -106,810 K. The company made 1,030 K in profit during its latest quarter, and -129,490 K in sales during its previous quarter.
